Juvenescence is a biopharmaceutical company that has raised USD $165 million since 2017 to build a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging.
As people age, complex changes occur at the genomic, cellular and tissue level, from the accumulation of DNA damage to mitochondrial dysfunction and altered intercellular communication.
These changes, among others, cause the diseases of aging that affect the elderly, and the chronic illnesses that are the biggest burden on the healthcare system.
Aging is the largest health problem facing the world today; two-thirds of all deaths worldwide are as a result of the aging process, with many years of degeneration reducing quality of life before death.
Our work is based on novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.
Juvenescence creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions.
Juvenescence aims to create a paradigm shift in addressing and treating disease.
Our goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence (”the state or period of being young”).
Ultimately, Juvenescence aims to get therapeutics to patients, and eradicate life-shattering diseases that cause people to suffer until death.
Juvenescence leverages its world-class team to translate rigorous science into disease-modifying therapeutics.
Our growing pipeline of therapeutic assets targets fundamental aging, regeneration, and the diseases of aging. Click below to the full pipeline to learn more about each company.
Juvenescence CEO Dr. Greg Bailey on near-term Longevity breakthroughs
Dr. Greg Bailey interview with Longevity.Technology: Juvenescence looks to bring on board a completely new mechanism for regeneration;Q3 product launch of a direct-to-consumer ketone ester drink product that is geroprotective, neuroprotective and cardioprotective;Reversing liver failure for people who would otherwise have to pay $700,000 for a liver transplant in the…Read more
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the…Read more
Please complete the form below to get in touch with the Juvenescence team.